David A. Fruman

David A. Fruman

Auto-generated profile, based on publicly available information

David A. Fruman

Department of Molecular Biology and Biochemistry, University of California, Irvine, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Cell
Verified
Journal Article
Closed access
DFDavid A. Fruman
David A. Fruman
HCHonyin Chiu
Honyin Chiu
BHBenjamin D. Hopkins
Benjamin D. Hopkins
SBShubha Bagrodia
Shubha Bagrodia
LCLewis C. Cantley
Lewis C. Cantley
RARobert T. Abraham
Robert T. Abraham

31 January 2014 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
DFDavid A. Fruman
David A. Fruman
CRChristian Rommel
Christian Rommel

4 December 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
VMVijaykumar S. Meli
Vijaykumar S. Meli
HAHamza Atcha
Hamza Atcha
PVPraveen Krishna Veerasubramanian
Praveen Krishna Veerasubramanian
RNRaji R. Nagalla
Raji R. Nagalla
TLThuy U. Luu
Thuy U. Luu
WLWendy F. Liu
Wendy F. Liu
Macrophages sense biophysical cues in the microenvironment via YAP to tune their inflammatory response.

13 January 2010 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MJMatthew R Janes
Matthew R Janes
JLJose J Limon
Jose J Limon
LSLomon So
Lomon So
JCJing Chen
Jing Chen
RLRaymond J Lim
Raymond J Lim
DFDavid A Fruman
David A Fruman
The protein kinase mTOR is known to contribute to cancer development. However, existing drugs targeting mTOR, such as rapamycin, have not been very effective at inhibiting cancer cell survival and also have the unwanted side effect of immunosuppression. Studying preclinical models of leukemia driven by the BCR-ABL oncogene, Matthew Janes et al. now show that a new mTOR inhibitor—which unlike previous ones is an ATP competitive inhibitor that targets the active site of the enzyme—can overcome these drawbacks. Targeting the mammalian target of rapamycin (mTOR) protein is a promising strategy for cancer therapy. The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs. We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation. We demonstrate that PP242, but not rapamycin, causes death of mouse and human leukemia cells. In vivo, PP242 delays leukemia onset and augments the effects of the current front-line tyrosine kinase inhibitors more effectively than does rapamycin. Unexpectedly, PP242 has much weaker effects than rapamycin on the proliferation and function of normal lymphocytes. PI-103, a less selective TORC1/2 inhibitor that also targets phosphoinositide 3-kinase (PI3K), is more immunosuppressive than PP242. These findings establish that Ph+ transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.

1 January 2012 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JLJose J. Limon
Jose J. Limon
DFDavid A. Fruman
David A. Fruman
Activation of phosphoinositide 3-kinase (PI3K) is required for B cell proliferation and survival. PI3K signaling also controls key aspects of B cell differentiation. Upon engagement of the B cell receptor (BCR), PI3K activation promotes Ca2+ mobilization and activation of NFκB-dependent transcription, events which are essential for B cell proliferation. PI3K also initiates a distinct signaling pathway involving the Akt and mTOR serine/threonine kinases. It has been generally assumed that activation of Akt and mTOR downstream of PI3K is essential for B cell function. However, Akt and mTOR have complex roles in B cell fate decisions and suppression of this pathway can enhance certain B cell responses while repressing others. In this review we will discuss genetic and pharmacological studies of Akt and mTOR function in normal B cells, and in malignancies of B cell origin.

24 February 2012 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
LSLomon So
Lomon So
DFDavid A. Fruman
David A. Fruman
Activation of PI3K (phosphoinositide 3-kinase) is a shared response to engagement of diverse types of transmembrane receptors. Depending on the cell type and stimulus, PI3K activation can promote different fates including proliferation, survival, migration and differentiation. The diverse roles of PI3K signalling are well illustrated by studies of lymphocytes, the cells that mediate adaptive immunity. Genetic and pharmacological experiments have shown that PI3K activation regulates many steps in the development, activation and differentiation of both B- and T-cells. These findings have prompted the development of PI3K inhibitors for the treatment of autoimmunity and inflammatory diseases. PI3K activation, however, has both positive and negative roles in immune system activation. Consequently, although PI3K suppression can attenuate immune responses it can also enhance inflammation, disrupt peripheral tolerance and promote autoimmunity. An exciting discovery is that a selective inhibitor of the p110δ catalytic isoform of PI3K, CAL-101, achieves impressive clinical efficacy in certain B-cell malignancies. A model is emerging in which p110δ inhibition disrupts signals from the lymphoid microenvironment, leading to release of leukaemia and lymphoma cells from their protective niche. These encouraging findings have given further momentum to PI3K drug development efforts in both cancer and immune diseases.